Author + information
- Received May 9, 2018
- Revision received September 5, 2018
- Accepted September 8, 2018
- Published online December 3, 2018.
- Davide Capodanno, MD, PhDa,
- Fernando Alfonso, MD, PhDb,
- Glenn N. Levine, MDc,
- Marco Valgimigli, MD, PhDd and
- Dominick J. Angiolillo, MD, PhDe,∗ (, )@UFHealthJax@UFMedicine
- aDivision of Cardiology, CAST, P.O. “G. Rodolico,” Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele,” University of Catania, Catania, Italy
- bDepartment of Cardiology, Hospital Universitario La Princesa, Madrid, Spain
- cDepartment of Medicine, Baylor College of Medicine, Houston, Texas
- dBern University Hospital, Bern, Switzerland
- eDivision of Cardiology, University of Florida College of Medicine, Jacksonville, Florida
- ↵∗Address for correspondence:
Dr. Dominick J. Angiolillo, University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, Florida 32209.
Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations. Prescribers of DAPT are confronted with a number of challenges that include selecting the appropriate P2Y12 inhibitor and determining the optimal duration of DAPT with the scope of minimizing the risk of ischemic and bleeding complications in light of each patient’s clinical characteristic and circumstance. Recently, a guideline writing committee from the American College of Cardiology/American Heart Association (ACC/AHA) and a task force from the European Society of Cardiology (ESC) released their respective focused update recommendations on “Duration of DAPT in Patients with CAD” (ACC/AHA) and “DAPT in CAD” (ESC). This paper aims to review the ACC/AHA and ESC updates for DAPT to delineate common domains, consistent messages, and differences in recommended management strategies across the Atlantic.
Dr. Capodanno has served on the advisory board of and received speaker’s honoraria from AstraZeneca and Bayer. Dr. Valgimigli has received grants from The Medicines Company, Terumo, and AstraZeneca; and has received personal fees from Terumo, St. Jude Vascular, and Abbott Vascular. Dr. Angiolillo has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has received payment for review activities from CeloNova and St. Jude Medical; has received institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions; and has received funding from the Scott R. MacKenzie Foundation and the National Institutes of Health/National Center for Advancing Translational Sciences Clinical and Translational Science Award to the University of Florida UL1 TR000064 and NIH/NHGRI U01 HG007269. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received May 9, 2018.
- Revision received September 5, 2018.
- Accepted September 8, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.